Want to see KZIA full AI Analyst Report?
KZIA Stock Chart & Stats
$6.44
-$0.01(-0.57%)
At close: 4:00 PM EST
$6.44
-$0.01(-0.57%)
Day’s Range― - ―
52-Week Range$4.86 - $17.40
Previous CloseN/A
Volume31.49K
Average Volume (3M)209.48K
Market Cap
$159.61M
Enterprise Value-$36.43M
Total Cash (Recent Filing)$69.39M
Total Debt (Recent Filing)$98.71K
Price to Earnings (P/E)―
Beta2.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,335,992
10 Day Avg. Volume60,839
30 Day Avg. Volume209,481
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.26
Price to Sales (P/S)248.45
P/FCF Ratio-0.79
Enterprise Value/Market Cap-0.23
Enterprise Value/Revenue-1.85K
Enterprise Value/Gross Profit-1.85K
Enterprise Value/Ebitda2.01
Forecast
1Y Price Target
$27.80Price Target Upside331.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway & No DebtA reported cash balance of about $46M with no debt and a stated runway into 2029 provides multi-year financing flexibility to advance clinical programs without immediate fundraising. This reduces near-term liquidity risk, supports parallel R&D paths and strengthens negotiating leverage for partnerships or licensing.
SETDB1 Platform LicenseAcquiring an exclusive SETDB1 epigenetic platform and lead MSETC candidate broadens Kazia's scientific moat beyond paxalisib, adds mechanistic diversity targeting immune evasion, and includes an AI discovery engine. This accelerates pipeline depth and partnering appeal, improving long-term R&D optionality and value creation paths.
Senior Scientific LeadershipAppointing Dr. Sudha Rao, the originator of paxalisib’s epigenetic framework, strengthens translational R&D and biomarker strategy. Her expertise raises the probability of robust clinical designs, faster target validation, and collaboration credibility—structural improvements to the company’s long-term drug development execution.
Bears Say
Collapsed Revenue BaseRevenue has contracted to a negligible level, demonstrating the company lacks commercial products and cannot self-fund development. This structural absence of recurring sales forces sustained dependence on capital markets or partners to finance trials, increasing dilution risk and constraining long-term financial independence.
Ongoing Cash BurnConsistent negative operating and free cash flow (roughly -$13.3M in 2025) means the company must repeatedly access external funding to advance programs. Persistent burn widens vulnerability to market access shocks and can force suboptimal financing or program prioritization, impacting long-term execution and shareholder dilution.
Negative Equity & Shrinking AssetsNegative equity and a materially smaller asset base reflect accumulated losses and reduced financial flexibility. This capital erosion can complicate securing non-dilutive partner deals, weaken balance-sheet bargaining power in collaborations or licensing, and signals underlying performance issues that may persist absent material clinical or commercial success.
Kazia Therapeutics News
KZIA FAQ
What was Kazia Therapeutics Limited’s price range in the past 12 months?
Kazia Therapeutics Limited lowest stock price was $4.86 and its highest was $17.40 in the past 12 months.
What is Kazia Therapeutics Limited’s market cap?
Kazia Therapeutics Limited’s market cap is $159.61M.
When is Kazia Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kazia Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Kazia Therapeutics Limited overvalued?
According to Wall Street analysts Kazia Therapeutics Limited’s price is currently Undervalued.
Does Kazia Therapeutics Limited pay dividends?
Kazia Therapeutics Limited does not currently pay dividends.
What is Kazia Therapeutics Limited’s EPS estimate?
Kazia Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kazia Therapeutics Limited have?
Kazia Therapeutics Limited has 11,335,992 shares outstanding.
What happened to Kazia Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kazia Therapeutics Limited?
Currently, no hedge funds are holding shares in KZIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kazia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.80 (331.68% Upside)
$27.80 (331.68% Upside)
Blogger Sentiment
Neutral
KZIA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 36.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-73.42%
12-Months-Change
Fundamentals
Return on Equity
-116.86%
Trailing 12-Months
Asset Growth
327.60%
Trailing 12-Months
Company Description
Kazia Therapeutics Limited
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
KZIA Stock 12 Month Forecast
Average Price Target
$27.80
▲(331.68% Upside)
Technical Analysis
Phio Pharmaceuticals
―
XTL Biopharmaceuticals Sponsored ADR
―
Marker Therapeutics
―
―
TransCode Therapeutics
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
9.82% Other Institutional Investors
90.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---